Q2 2018 EPS Estimates for Crispr Theraptc Raised by Oppenheimer Holdings (CRSP)
Crispr Theraptc (NASDAQ:CRSP) – Equities research analysts at Oppenheimer Holdings boosted their Q2 2018 EPS estimates for Crispr Theraptc in a report issued on Monday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous forecast of ($0.81). Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Crispr Theraptc’s Q3 2018 earnings at ($0.67) EPS and Q4 2018 earnings at ($1.06) EPS.
Several other research firms have also commented on CRSP. Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Barclays PLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Crispr Theraptc in a report on Friday, September 8th. Cann assumed coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Finally, SunTrust Banks, Inc. assumed coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.08.
Crispr Theraptc (NASDAQ:CRSP) traded up 1.15% during midday trading on Wednesday, reaching $19.34. The company’s stock had a trading volume of 205,558 shares. Crispr Theraptc has a one year low of $13.75 and a one year high of $25.00. The stock’s 50 day moving average price is $18.57 and its 200-day moving average price is $18.57. The stock’s market cap is $785.03 million.
Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $3.29 million. The company’s quarterly revenue was up 350.0% compared to the same quarter last year.
Hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC acquired a new stake in Crispr Theraptc in the first quarter valued at approximately $110,000. Wells Fargo & Company MN increased its position in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Crispr Theraptc in the second quarter valued at approximately $206,000. Vanguard Group Inc. purchased a new stake in shares of Crispr Theraptc in the second quarter valued at approximately $273,000. Finally, Monashee Investment Management LLC increased its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. Institutional investors own 23.90% of the company’s stock.
In related news, CEO Rodger Novak sold 18,470 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total value of $383,437.20. Following the completion of the transaction, the chief executive officer now owns 1,148,007 shares of the company’s stock, valued at approximately $23,832,625.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 88,011 shares of the company’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $19.79, for a total value of $1,741,737.69. The disclosure for this sale can be found here. Insiders have sold a total of 625,615 shares of company stock worth $11,727,715 over the last 90 days. Insiders own 39.98% of the company’s stock.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.